Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination

被引:3
|
作者
van den Biggelaar, Anita H. J. [1 ]
Richmond, Peter C. [2 ]
Fuery, Angela [2 ,5 ]
Anderson, Denise [1 ]
Opa, Christine [3 ]
Saleu, Gerard [3 ]
Lai, Mildred [3 ]
Francis, Jacinta P. [3 ]
Alpers, Michael P. [4 ]
Pomat, William S. [3 ]
Lehmann, Deborah [1 ]
机构
[1] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia
[2] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA, Australia
[3] Papua New Guinea Inst Med Res, Goroka, Eastern Highlan, Papua N Guinea
[4] Curtin Univ, Sch Hlth Sci, Int Hlth, Perth, WA, Australia
[5] Baylor Coll Med, Houston, TX 77030 USA
来源
PLOS ONE | 2017年 / 12卷 / 10期
基金
英国医学研究理事会; 英国惠康基金; 澳大利亚国家健康与医学研究理事会;
关键词
RESPIRATORY-TRACT INFECTIONS; STREPTOCOCCUS-PNEUMONIAE; IMMUNE-RESPONSE; HYPORESPONSIVENESS; IMMUNOGENICITY; DISEASE; PERSISTENCE; 7-VALENT; EFFICACY; BOOSTER;
D O I
10.1371/journal.pone.0185877
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Trial design In an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose of 23-valent pneumococcal polysaccharide vaccine (PPV23) at 9 months of age. We here studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in these children at 3-5 years of age (n = 132), and in 121 community controls of a similar age with no prior pneumococcal vaccination. Methods Circulating IgG antibody titers to all PCV7 and PPV23-only serotypes 2, 5 and 7F were measured before and after challenge with 1/5 th of a normal PPV23 dose. Serotype-specific memory B-cells were enumerated at 10 months and 3-5 years of age for a subgroup of study children. Results Serotype-specific IgG antibody titers before and after challenge were similar for children who received PCV7/PPV23, PPV23 only, or no pneumococcal vaccines. Before challenge, at least 89% and 59% of children in all groups had serotype-specific titers similar to 0.35 mu g/ml and similar to 1.0 mu g/ml, respectively. Post-challenge antibody titers were higher or similar to pre-challenge titers for most children independent of pneumococcal vaccination history. The rise in antibody titers was significantly lower when pre-challenge titers were higher. Overall the relative number of serotype-specific memory B-cells remained the same or increased between 10 months and 3-5 years of age, and there were no differences in serotype-specific memory B-cell numbers at 3-5 years of age between the three groups. Conclusions Immunity induced by PCV7 and/or PPV23 immunization in infancy does not exceed that of naturally acquired immunity in 3-5-year-old children living in a highly endemic area. Also, there was no evidence that PPV23 immunization in the first year of life following PCV7 priming induces longer-term hypo-responsiveness.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Short Communication Divergent serotype distribution between children with otitis media and those without in the pneumococcal conjugate vaccine era
    Chen, Chih-Ho
    Chen, Chyi-Liang
    Arguedas, Adriano
    Southern, Joanna
    Hsiao, Chang-Chun
    Chiu, Cheng-Hsun
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2020, 53 (06) : 1035 - 1038
  • [42] Invasive pneumococcal disease in children younger than 5 years in Navarra, Spain (2000-2005). Impact of the conjugate vaccine
    Barricarte, Aurelio
    Gil-Setas, Alberto
    Torroba, Luis
    Castilla, Jesus
    Petit, Alba
    Polo, Isabel
    Arriazu, Maite
    Irisarri, Fatima
    Cenoz, Manuel Garcia
    MEDICINA CLINICA, 2007, 129 (02): : 41 - 45
  • [43] Pneumococcal Carriage, Serotype Distribution, and Risk Factors in Children With Community-Acquired Pneumonia, 5 Years After Introduction of the 10-Valent Pneumococcal Conjugate Vaccine in Ethiopia
    Negash, Abel Abera
    Asrat, Daniel
    Abebe, Workeabeba
    Hailemariam, Tewodros
    Gebre, Meseret
    Verhaegen, Jan
    Aseffa, Abraham
    Vaneechoutte, Mario
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (06):
  • [44] Safety and Antibody Response, Including Antibody Persistence for 5 Years, after Primary Vaccination or Revaccination with Pneumococcal Polysaccharide Vaccine in Middle-Aged and Older Adults
    Musher, Daniel M.
    Manoff, Susan B.
    Liss, Charlie
    McFetridge, Richard D.
    Marchese, Rocio D.
    Bushnell, Bonnie
    Alvarez, Frances
    Painter, Carla
    Blum, Michael D.
    Silber, Jeffrey L.
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (04) : 516 - 524
  • [45] Impact of 10-Valent Pneumococcal Conjugate Vaccine Introduction on Pneumococcal Carriage and Antibiotic Susceptibility Patterns Among Children Aged <5 Years and Adults With Human Immunodeficiency Virus Infection: Kenya, 2009-2013
    Kobayashi, Miwako
    Bigogo, Godfrey
    Kim, Lindsay
    Mogeni, Ondari D.
    Conklin, Laura M.
    Odoyo, Arthur
    Odiembo, Herine
    Pimenta, Fabiana
    Ouma, Dominic
    Harris, Aaron M.
    Odero, Kennedy
    Milucky, Jennifer L.
    Ouma, Alice
    Aol, George
    Audi, Allan
    Onyango, Clayton
    Cosmas, Leonard
    Jagero, Geofrey
    Farrar, Jennifer L.
    Carvalho, Maria da Gloria
    Whitney, Cynthia G.
    Breiman, Robert F.
    Lessa, Fernanda C.
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (05) : 814 - 826
  • [46] Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults A randomized open-label trial
    Juergens, Christine
    de Villiers, Pierre J. T.
    Moodley, Keymanthri
    Jayawardene, Deepthi
    Jansen, Kathrin U.
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (05) : 1343 - 1353
  • [47] Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study
    Hernandez, Sergi
    Navas, Encarna
    Aznar-Lou, Ignacio
    Ciruela, Pilar
    Garcia-Garcia, Juan Jose
    Moraga-Llop, Fernando
    Munoz-Almagro, Carmen
    Codina, Gemma
    de Sevilla, Mariona F.
    Gonzalez-Peris, Sebastia
    Esteva, Cristina
    Planes, Ana Maria
    Izquierdo, Conchita
    Martinez-Osorio, Johanna
    Campins, Magda
    Uriona, Sonia
    Salleras, Luis
    Serrano-Blanco, Antoni
    Jane, Mireia
    Dominguez, Angela
    VACCINES, 2020, 8 (03) : 1 - 17
  • [48] Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
    Cordonnier, Catherine
    Ljungman, Per
    Juergens, Christine
    Maertens, Johan
    Selleslag, Dominik
    Sundaraiyer, Vani
    Giardina, Peter C.
    Clarke, Keri
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (03) : 313 - 323
  • [49] 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study
    De Montalembert, Mariane
    Abboud, Miguel R.
    Fiquet, Anne
    Inati, Adlette
    Lebensburger, Jeffrey D.
    Kaddah, Normeen
    Mokhtar, Galila
    Piga, Antonio
    Halasa, Natasha
    Inusa, Baba
    Rees, David C.
    Heath, Paul T.
    Telfer, Paul
    Driscoll, Catherine
    Al Hajjar, Sami
    Tozzi, Alberto
    Jiang, Qin
    Emini, Emilio A.
    Gruber, William C.
    Gurtman, Alejandra
    Scott, Daniel A.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (08) : 1427 - 1436
  • [50] Pneumococcal carriage and antibiotic susceptibility patterns from two cross-sectional colonization surveys among children aged < 5 years prior to the introduction of 10-valent pneumococcal conjugate vaccine - Kenya, 2009-2010
    Kobayashi, Miwako
    Conklin, Laura M.
    Bigogo, Godfrey
    Jagero, Geofrey
    Hampton, Lee
    Fleming-Dutra, Katherine E.
    Junghae, Muthoni
    Carvalho, Maria da Gloria
    Pimenta, Fabiana
    Beall, Bernard
    Taylor, Thomas
    Laserson, Kayla F.
    Vulule, John
    Van Beneden, Chris
    Kim, Lindsay
    Feikin, Daniel R.
    Whitney, Cynthia G.
    Breiman, Robert F.
    BMC INFECTIOUS DISEASES, 2017, 17